Waldenstrom Macroglobulinemia: FDA Updates

Home » Understanding Lymphoma » About Lymphoma and Subtypes » Non-Hodgkin Lymphoma » Waldenstrom Macroglobulinemia » Waldenstrom Macroglobulinemia: FDA Updates

What is Lymphoma?

Home » Understanding Lymphoma » About Lymphoma and Subtypes » Non-Hodgkin Lymphoma » Waldenstrom Macroglobulinemia » Waldenstrom Macroglobulinemia: FDA Updates

Waldenström Macroglobulinemia: FDA Updates

August 31, 2021 – the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with Waldenstrӧm macroglobulinemia (WM). More Information.

July 23, 2019 – The U.S. Food and Drug Administration (FDA) approved the use of rituximab-pvvr (RUXIENCE), a biosimilar to rituximab (RITUXAN), for the treatment of CD20-positive non-Hodgkin B-cell lymphoma and chronic lymphocytic leukemia.

August 27, 2018 – The U.S. Food and Drug Administration (FDA) approved ibrutinib (IMBRUVICA) plus rituximab (RITUXAN) for the first chemotherapy-free treatment for adult patients with Waldenstrom’s macroglobulinemia (WM). More Information.